B-type natriuretic peptide (BNP) predicts 90-day mortality and need for paracentesis in cirrhotic patients without systolic heart failure

Abstract Fluid overload is a common complication in patients with cirrhosis. B-type natriuretic peptide (BNP) is a marker of increased blood volume, commonly used in heart failure, that has been shown to be elevated in patients with liver disease. This study examined if BNP levels can be used to det...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tiago Araujo, Ishaan Vohra, Pedro Palacios, Vatsala Katiyar, Estefania Flores, Tejinder Randhawa, Yuchen Wang, Yazan Abu-Omar, Vijaya Mukthinuthalapati, Hemant Mutneja, Sanjay A. Patel, Bashar Attar
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/fd0760b38b47429683a3d984c7aec330
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:fd0760b38b47429683a3d984c7aec330
record_format dspace
spelling oai:doaj.org-article:fd0760b38b47429683a3d984c7aec3302021-12-02T15:23:47ZB-type natriuretic peptide (BNP) predicts 90-day mortality and need for paracentesis in cirrhotic patients without systolic heart failure10.1038/s41598-020-78946-32045-2322https://doaj.org/article/fd0760b38b47429683a3d984c7aec3302021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-78946-3https://doaj.org/toc/2045-2322Abstract Fluid overload is a common complication in patients with cirrhosis. B-type natriuretic peptide (BNP) is a marker of increased blood volume, commonly used in heart failure, that has been shown to be elevated in patients with liver disease. This study examined if BNP levels can be used to determine prognosis and predict worsening of ascites in patients with cirrhosis without concomitant heart disease. A retrospective study was performed at a large urban hospital in Chicago, Illinois and included 430 patients with cirrhosis who had BNP levels ordered during their hospital stay. Patients with clinical heart failure, arrhythmias or pulmonary hypertension were excluded. The primary outcome was 90-day mortality and the secondary outcome was a requirement for therapeutic paracentesis in the 90 days following BNP results. 53 patients (12%) had BNP levels ≥ 300 pg/mL. They had significantly increased serum levels of creatinine, bilirubin, and International Normalized Ratio (INR) when compared to those with BNP < 300 pg/mL. Patients with higher BNP had significantly higher mortality rates (HR 3.49; p = 0.037) and were more likely to require therapeutic paracentesis (HR 2.26; p = 0.02) in the next 90 days. A BNP ≥ 300 pg/mL had specificity of 88.2% in predicting 90-day mortality. BNP may serve as a practical and reliable marker of underlying disease severity in patients with cirrhosis, with potential to be included in prognostication tools for assessment of end-stage liver disease.Tiago AraujoIshaan VohraPedro PalaciosVatsala KatiyarEstefania FloresTejinder RandhawaYuchen WangYazan Abu-OmarVijaya MukthinuthalapatiHemant MutnejaSanjay A. PatelBashar AttarNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Tiago Araujo
Ishaan Vohra
Pedro Palacios
Vatsala Katiyar
Estefania Flores
Tejinder Randhawa
Yuchen Wang
Yazan Abu-Omar
Vijaya Mukthinuthalapati
Hemant Mutneja
Sanjay A. Patel
Bashar Attar
B-type natriuretic peptide (BNP) predicts 90-day mortality and need for paracentesis in cirrhotic patients without systolic heart failure
description Abstract Fluid overload is a common complication in patients with cirrhosis. B-type natriuretic peptide (BNP) is a marker of increased blood volume, commonly used in heart failure, that has been shown to be elevated in patients with liver disease. This study examined if BNP levels can be used to determine prognosis and predict worsening of ascites in patients with cirrhosis without concomitant heart disease. A retrospective study was performed at a large urban hospital in Chicago, Illinois and included 430 patients with cirrhosis who had BNP levels ordered during their hospital stay. Patients with clinical heart failure, arrhythmias or pulmonary hypertension were excluded. The primary outcome was 90-day mortality and the secondary outcome was a requirement for therapeutic paracentesis in the 90 days following BNP results. 53 patients (12%) had BNP levels ≥ 300 pg/mL. They had significantly increased serum levels of creatinine, bilirubin, and International Normalized Ratio (INR) when compared to those with BNP < 300 pg/mL. Patients with higher BNP had significantly higher mortality rates (HR 3.49; p = 0.037) and were more likely to require therapeutic paracentesis (HR 2.26; p = 0.02) in the next 90 days. A BNP ≥ 300 pg/mL had specificity of 88.2% in predicting 90-day mortality. BNP may serve as a practical and reliable marker of underlying disease severity in patients with cirrhosis, with potential to be included in prognostication tools for assessment of end-stage liver disease.
format article
author Tiago Araujo
Ishaan Vohra
Pedro Palacios
Vatsala Katiyar
Estefania Flores
Tejinder Randhawa
Yuchen Wang
Yazan Abu-Omar
Vijaya Mukthinuthalapati
Hemant Mutneja
Sanjay A. Patel
Bashar Attar
author_facet Tiago Araujo
Ishaan Vohra
Pedro Palacios
Vatsala Katiyar
Estefania Flores
Tejinder Randhawa
Yuchen Wang
Yazan Abu-Omar
Vijaya Mukthinuthalapati
Hemant Mutneja
Sanjay A. Patel
Bashar Attar
author_sort Tiago Araujo
title B-type natriuretic peptide (BNP) predicts 90-day mortality and need for paracentesis in cirrhotic patients without systolic heart failure
title_short B-type natriuretic peptide (BNP) predicts 90-day mortality and need for paracentesis in cirrhotic patients without systolic heart failure
title_full B-type natriuretic peptide (BNP) predicts 90-day mortality and need for paracentesis in cirrhotic patients without systolic heart failure
title_fullStr B-type natriuretic peptide (BNP) predicts 90-day mortality and need for paracentesis in cirrhotic patients without systolic heart failure
title_full_unstemmed B-type natriuretic peptide (BNP) predicts 90-day mortality and need for paracentesis in cirrhotic patients without systolic heart failure
title_sort b-type natriuretic peptide (bnp) predicts 90-day mortality and need for paracentesis in cirrhotic patients without systolic heart failure
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/fd0760b38b47429683a3d984c7aec330
work_keys_str_mv AT tiagoaraujo btypenatriureticpeptidebnppredicts90daymortalityandneedforparacentesisincirrhoticpatientswithoutsystolicheartfailure
AT ishaanvohra btypenatriureticpeptidebnppredicts90daymortalityandneedforparacentesisincirrhoticpatientswithoutsystolicheartfailure
AT pedropalacios btypenatriureticpeptidebnppredicts90daymortalityandneedforparacentesisincirrhoticpatientswithoutsystolicheartfailure
AT vatsalakatiyar btypenatriureticpeptidebnppredicts90daymortalityandneedforparacentesisincirrhoticpatientswithoutsystolicheartfailure
AT estefaniaflores btypenatriureticpeptidebnppredicts90daymortalityandneedforparacentesisincirrhoticpatientswithoutsystolicheartfailure
AT tejinderrandhawa btypenatriureticpeptidebnppredicts90daymortalityandneedforparacentesisincirrhoticpatientswithoutsystolicheartfailure
AT yuchenwang btypenatriureticpeptidebnppredicts90daymortalityandneedforparacentesisincirrhoticpatientswithoutsystolicheartfailure
AT yazanabuomar btypenatriureticpeptidebnppredicts90daymortalityandneedforparacentesisincirrhoticpatientswithoutsystolicheartfailure
AT vijayamukthinuthalapati btypenatriureticpeptidebnppredicts90daymortalityandneedforparacentesisincirrhoticpatientswithoutsystolicheartfailure
AT hemantmutneja btypenatriureticpeptidebnppredicts90daymortalityandneedforparacentesisincirrhoticpatientswithoutsystolicheartfailure
AT sanjayapatel btypenatriureticpeptidebnppredicts90daymortalityandneedforparacentesisincirrhoticpatientswithoutsystolicheartfailure
AT basharattar btypenatriureticpeptidebnppredicts90daymortalityandneedforparacentesisincirrhoticpatientswithoutsystolicheartfailure
_version_ 1718387304465170432